Ultragenyx Pharmaceutical RARE Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's other accrued liabilities?
- Ultragenyx Pharmaceutical (RARE) reported other accrued liabilities of $17M in Q1 2026.
- How has Ultragenyx Pharmaceutical's other accrued liabilities changed year-over-year?
- Ultragenyx Pharmaceutical's other accrued liabilities increased by 407.8% year-over-year, from $3.35M to $17M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.